Steven A. Feldman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Steven A. Feldman has a total of 153 co-authors. Here are the top co-authors by number of shared publications:
- Crystal L. Mackall
Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, USA
64 shared publications - Anne Marijn Kramer
Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, California
63 shared publications - David Bernard Miklos
Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, USA
63 shared publications - Hrishikesh Krishna Srinagesh
Stanford University School of Medicine
63 shared publications - Lori Muffly
Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, USA
63 shared publications - Bita Sahaf
Stanford University 5 Center for Cancer Cell Therapy, Stanford Cancer Institute Stanford, California
62 shared publications
Latest Publications
- 29 July 2026
- Published by Elsevier in Cytotherapy
- Vol. 28 (12)
Integrated T-cell enrichment, static transduction, and expansion in gas-permeable bioreactors for adoptive cell therapy
- 29 July 2026
- Published by Elsevier in Cytotherapy
- Vol. 28 (12)
Integrated T-cell enrichment, static transduction, and expansion in gas-permeable bioreactors for adoptive cell therapy
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
Hemogram analysis prior to leukapheresis for CAR22
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
Hemogram analysis prior to leukapheresis for CAR22
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
Sensitivity analysis for handling residual CAR19 qPCR data below limit of quantification (LOQ) in leukapheresis material
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
Sensitivity analysis for handling residual CAR19 qPCR data below limit of quantification (LOQ) in leukapheresis material
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
Linear regression analysis of CAR22 transduction efficiency, vector copy number (VCN) and T cell subsets in CD4/CD8 enrichment material and CAR22 product (A) Linear regression of CAR22 transduction efficiency versus T cell subsets in CD4/CD8 enrichment material. (B) Linear regression of CAR22 transduction efficiency versus T cell subsets in the products. (C) Linear regression of CAR22 VCN versus T cell subsets in CD4/CD8 enrichment material. (D) Linear regression of CAR22 VCN versus T cell subsets in the products.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
Linear regression analysis of CAR22 transduction efficiency, vector copy number (VCN) and T cell subsets in CD4/CD8 enrichment material and CAR22 product (A) Linear regression of CAR22 transduction efficiency versus T cell subsets in CD4/CD8 enrichment material. (B) Linear regression of CAR22 transduction efficiency versus T cell subsets in the products. (C) Linear regression of CAR22 VCN versus T cell subsets in CD4/CD8 enrichment material. (D) Linear regression of CAR22 VCN versus T cell subsets in the products.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
Comparative analysis of Comparative analysis of T cell subsets of CD4/CD8 enrichment material during CAR22 manufacturing process. (A) CD4+ and (B) CD8+ T cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
Comparative analysis of Comparative analysis of T cell subsets of CD4/CD8 enrichment material during CAR22 manufacturing process. (A) CD4+ and (B) CD8+ T cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
Comparative analysis of CAR22 transduction rate, vector copy number (VCN) and T cell subset in CAR22 products between patients who experienced disease progression (PD) within 90 days versus more than 90 days after CAR19 therapy (A) Patients who experienced PD within 90 days post-CAR19 infusion exhibited lower CAR22 transduction rates and VCN in their CAR22 products compared to those who PD after 90 days. (B) The T cell subset was similar between the 2 groups.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
Comparative analysis of CAR22 transduction rate, vector copy number (VCN) and T cell subset in CAR22 products between patients who experienced disease progression (PD) within 90 days versus more than 90 days after CAR19 therapy (A) Patients who experienced PD within 90 days post-CAR19 infusion exhibited lower CAR22 transduction rates and VCN in their CAR22 products compared to those who PD after 90 days. (B) The T cell subset was similar between the 2 groups.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
Cohort 2: Patient demographics upon receiving CAR19 or CAR22 therapies
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
Cohort 2: Patient demographics upon receiving CAR19 or CAR22 therapies
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
CD39 expression on CD4+ and CD8+ CAR22, stratified by median expression levels (High/Low) or using a 20% cutoff, and its correlation with CAR22 expansion as measured by flow cytometry and qPCR, treatment response, and survival outcomes. (A) The CD39 expression level on CD4+ or CD8+ CAR22 in the product, stratified by median (> median or < median) or using a 20% cutoff, shows no significant difference in CAR22 maximal expansion (CMax) measured by flow cytometry in peripheral blood (PB) after infusion. (B) CD39 expression on CD4+ or CD8+ CAR22, stratified by median, shows no significant difference in CAR22 area under the curve from day 0 to 28 (AUC0-28) post-infusion as measured by flow cytometry in PB. (C) CD39 expression on CD4+ or CD8+ CAR22, stratified by median, shows no significant difference in CAR22 CMax and AUC0-28 post-infusion as measured by qPCR in PB. (D) CD39 expression on CD4+ or CD8+ CAR22, stratified by median, shows no significant difference in complete response rate, progression-free survival, or overall survival. Dotted lines represent the 95% confidence interval.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
CD39 expression on CD4+ and CD8+ CAR22, stratified by median expression levels (High/Low) or using a 20% cutoff, and its correlation with CAR22 expansion as measured by flow cytometry and qPCR, treatment response, and survival outcomes. (A) The CD39 expression level on CD4+ or CD8+ CAR22 in the product, stratified by median (> median or < median) or using a 20% cutoff, shows no significant difference in CAR22 maximal expansion (CMax) measured by flow cytometry in peripheral blood (PB) after infusion. (B) CD39 expression on CD4+ or CD8+ CAR22, stratified by median, shows no significant difference in CAR22 area under the curve from day 0 to 28 (AUC0-28) post-infusion as measured by flow cytometry in PB. (C) CD39 expression on CD4+ or CD8+ CAR22, stratified by median, shows no significant difference in CAR22 CMax and AUC0-28 post-infusion as measured by qPCR in PB. (D) CD39 expression on CD4+ or CD8+ CAR22, stratified by median, shows no significant difference in complete response rate, progression-free survival, or overall survival. Dotted lines represent the 95% confidence interval.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
Comparative analysis of exhaustion markers expression of CD4/CD8 enrichment material during CAR22 manufacturing process Expression of exhaustion markers, including CD39, lymphocyte-activation gene 3 (LAG-3), programmed cell death protein 1 (PD1), and T-cell immunoglobulin mucin-3 (TIM3), in (A) CD4+ and (B) CD8+ T-cells showed no significant difference between the two groups.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
Comparative analysis of exhaustion markers expression of CD4/CD8 enrichment material during CAR22 manufacturing process Expression of exhaustion markers, including CD39, lymphocyte-activation gene 3 (LAG-3), programmed cell death protein 1 (PD1), and T-cell immunoglobulin mucin-3 (TIM3), in (A) CD4+ and (B) CD8+ T-cells showed no significant difference between the two groups.